Thomas Garton

Thomas Garton

Auto-generated profile, based on publicly available information

Thomas Garton

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2021 in Nature
Verified
Journal Article
Closed access
PDF file
MAMartina Absinta
Martina Absinta
DMDragan Maric
Dragan Maric
MGMarjan Gharagozloo
Marjan Gharagozloo
TGThomas Garton
Thomas Garton
MSMatthew D. Smith
Matthew D. Smith
DRDaniel Reich
Daniel Reich

29 November 2016 in Stroke and Vascular Neurology
Verified
Journal Article
Open access
PDF file
TGThomas Garton
Thomas Garton
RKRichard F Keep
Richard F Keep
YHYa Hua
Ya Hua
GXGuohua Xi
Guohua Xi
Intracranial haemorrhages, including intracerebral haemorrhage (ICH), intraventricular haemorrhage (IVH) and subarachnoid haemorrhage (SAH), are leading causes of morbidity and mortality worldwide. In addition, haemorrhage contributes to tissue damage in traumatic brain injury (TBI). To date, efforts to treat the long-term consequences of cerebral haemorrhage have been unsatisfactory. Incident rates and mortality have not showed significant improvement in recent years. In terms of secondary damage following haemorrhage, it is becoming increasingly apparent that blood components are of integral importance, with haemoglobin-derived iron playing a major role. However, the damage caused by iron is complex and varied, and therefore, increased investigation into the mechanisms by which iron causes brain injury is required. As ICH, IVH, SAH and TBI are related, this review will discuss the role of iron in each, so that similarities in injury pathologies can be more easily identified. It summarises important components of normal brain iron homeostasis and analyses the existing evidence on iron-related brain injury mechanisms. It further discusses treatment options of particular promise.

1 December 2014 in Neurosurgery
Verified
Journal Article
Closed access
PDF file
JSJennifer M. Strahle
Jennifer M. Strahle
TGThomas Garton
Thomas Garton
ABAhmad A. Bazzi
Ahmad A. Bazzi
HKHarish Kilaru
Harish Kilaru
HGHugh J.L. Garton
Hugh J.L. Garton
GXGuohua Xi
Guohua Xi
Background:. Neonatal germinal matrix hemorrhage/intraventricular hemorrhage is common and often results in hydrocephalus. The pathogenesis of posthemor

7 October 2015 in Translational Stroke Research
Verified
Journal Article
Closed access
PDF file
HZHao Zhao
Hao Zhao
TGThomas Garton
Thomas Garton
RKRichard F. Keep
Richard F. Keep
YHYa Hua
Ya Hua
GXGuohua Xi
Guohua Xi

30 June 2016 in Translational Stroke Research
Verified
Journal Article
Closed access
PDF file
TGThomas Garton
Thomas Garton
RKRichard F. Keep
Richard F. Keep
DWD. Andrew Wilkinson
D. Andrew Wilkinson
JSJennifer M. Strahle
Jennifer M. Strahle
YHYa Hua
Ya Hua
GXGuohua Xi
Guohua Xi

30 October 2017 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
TGThomas Garton
Thomas Garton
YHYa Hua
Ya Hua
JXJianming Xiang
Jianming Xiang
GXGuohua Xi
Guohua Xi
RKRichard F. Keep
Richard F. Keep
Introduction: Intraventricular hemorrhage (IVH) affects both premature infants and adults. In both demographics, it has high mortality and morbidity. There is no FDA approved therapy that improves neurological outcome in either population highlighting the need for additional focus on therapeutic targets and treatments emerging from preclinical studies. Areas covered: IVH induces both initial injury linked to the physical effects of the blood (mass effect) and secondary injury linked to the brain response to the hemorrhage. Preclinical studies have identified multiple secondary injury mechanisms following IVH, and particularly the role of blood components (e.g. hemoglobin, iron, thrombin). This review, with an emphasis on pre-clinical IVH research, highlights therapeutic targets and treatments that may be of use in prevention, acute care, or repair of damage. Expert opinion: An IVH is a potentially devastating event. Progress has been made in elucidating injury mechanisms, but this has still to translate to the clinic. Some pathways involved in injury also have beneficial effects (coagulation cascade/inflammation). A greater understanding of the downstream pathways involved in those pathways may allow therapeutic development. Iron chelation (deferoxamine) is in clinical trial for intracerebral hemorrhage and preclinical data suggest it may be a potential treatment for IVH.